

■ Granta cells

Human Granta cells were isolated from the pleural effusion of a patient with non-hogkin's mantle cells lymphoma.

■ Tumour growth *in vivo*

The cells were collected from a tissue culture flask and injected subcutaneously in the right flank of SCID-CB17 mice. The resulting tumours were monitored by measuring two diameters with calipers, and extrapolating the volume to a sphere.

The mice bearing Granta tumours can be treated by intra-peritoneal, intra-venous, intra-tumoral or subcutaneous injection of the compounds. Per os administration is also possible.




Figure 1: Tumour growth curve of the Granta cells as xenograft
Mean ± SEM (n=8; take rate 87.5%)

Antineo can also perform an intra-medullar implantation.

■ Standard-Of-Care Drug Reponses

rituximab 30 mg/kg qw → Response




Figure 2: Effect of rituximab treatment on Granta tumour growth
Mean ± SEM (n=3 per group; take rate 100%)

A Granta resistant to rituximab model, developed *in vivo* without genetic modifications, are available at Antineo (model ID Granta rituxR).